Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PR-3 (cyclosporine)
- Development stage
- Preclinical
- Lead developer
- Novartis
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Ophthalmic
01
Overview
PR-3 is an ophthalmic nanoemulsion formulation of cyclosporine developed by Puripharm for the treatment of dry eye disease and severe keratitis. Cyclosporine is a small molecule calcineurin inhibitor that works by binding to cyclophilin A, forming a complex that inhibits the phosphatase activity of calcineurin. This inhibition prevents the dephosphorylation and subsequent nuclear translocation of the nuclear factor of activated T-cells (NFAT), thereby reducing the production of pro-inflammatory cytokines such as interleukin-2 (IL-2). The nanoemulsion formulation is designed to enhance the solubility and ocular surface retention of the hydrophobic cyclosporine molecule, potentially improving therapeutic efficacy and patient comfort compared to traditional oil-based formulations.
- Other names
- CiclosporinCyclosporine ACyclosporine nanoemulsion
02
Targets
CN (Calcineurin)PPIA (Peptidyl-prolyl cis-trans isomerase A)
Beyond the preview
Go deeper on PR-3 (cyclosporine).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PR-3 (cyclosporine).